Metenolone enanthate
 |
|
| Clinical data | |
|---|---|
| Trade names | Primobolan Depot |
| Routes of administration |
Intramuscular injection |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Biological half-life | IM: 4–5 days |
| Identifiers | |
|
|
| Synonyms | NSC-64967; SH-601; SQ-16374 |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ECHA InfoCard | 100.005.584 |
| Chemical and physical data | |
| Formula | C27H42O3 |
| Molar mass | 414.621 g/mol |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?)
|
|
Metenolone enanthate, or methenolone enanthate, is a dihydrotestosterone (DHT)-based anabolic-androgenic steroid (AAS). It is an ester derivative of metenolone sold commonly under the brand name Primobolan Depot (injectable). When it interacts with the aromatase enzyme it does not form any estrogens. It is used by people who are very susceptible to estrogenic side effects, having lower estrogenic properties than nandrolone. Metenolone, in form of enanthate and acetate (see metenolone acetate), is available as an injection or as an oral formulation, respectively. The injection is regarded as having a higher bioavailability. It is an enanthate ester which is quite long-acting. Because it by-passes hepatic breakdown on the first pass, it also has a higher survival rate. The tablets are in a short-lived acetate form. Metenolone is not 17-alpha-alkylated, but 1-methylated for oral bioavailability. This reduces the stress on the liver, but also the availability. In doses of 200 mg per week or less (intramuscular) blood pressure is rarely altered.
Metenolone enanthate can be suppressive of the hypothalamic-pituitary-gonadal axis.
...
Wikipedia